{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T21:16:52Z","timestamp":1648847812156},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.lpm.2008.12.037","type":"journal-article","created":{"date-parts":[[2010,1,15]],"date-time":"2010-01-15T01:06:11Z","timestamp":1263517571000},"page":"446-451","source":"Crossref","is-referenced-by-count":4,"title":["New trends in hepatitis C management"],"prefix":"10.1016","volume":"39","author":[{"given":"Vincent","family":"Mallet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana\u00efs","family":"Vallet-Pichard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2008.12.037_bib1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis\u00a0C virus infection\u00a0: a meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","article-title":"Sustained virological response to interferon-\u03b1 is associated with improved outcome in HCV-related cirrhosis\u00a0: a retrospective study","volume":"45","author":"Bruno","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","article-title":"Brief communication\u00a0: the relationship of regression of cirrhosis to outcome in chronic hepatitis C","volume":"149","author":"Mallet","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2008.12.037_bib4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2008.12.037_bib5","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0149-2918(02)80042-X","article-title":"Pegylated interferons for the treatment of chronic hepatitis C infection","volume":"24","author":"Luxon","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.lpm.2008.12.037_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.antiviral.2003.08.009","article-title":"Combined antiviral options for the treatment of chronic hepatitis C","volume":"60","author":"Medina","year":"2003","journal-title":"Antiviral Res"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2008.12.037_bib7","first-page":"23","article-title":"Pharmacokinetics of peginterferons","volume":"23","author":"Zeuzem","year":"2003","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.lpm.2008.12.037_bib8","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/hep.21670","article-title":"Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1","volume":"46","author":"Jacobson","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib9","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2008.12.037_bib10","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-\u03b1-2a and ribavirin combination therapy in chronic hepatitis C\u00a0: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2008.12.037_bib11","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C\u00a0: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2008.12.037_bib12","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/gut.2004.057182","article-title":"Peginterferon {\u03b1}-2b and ribavirin therapy in chronic hepatitis C genotype 4\u00a0: impact of treatment duration and viral kinetics on sustained virological response","volume":"54","author":"Kamal","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.lpm.2008.12.037_bib13","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa032502","article-title":"Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites","volume":"350","author":"Muir","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2008.12.037_bib14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1053\/jhep.2003.50364","article-title":"Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C","volume":"38","author":"Davis","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib15","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0016-5085(99)70402-6","article-title":"A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia","volume":"117","author":"Shiffman","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lpm.2008.12.037_bib16","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/hep.21159","article-title":"Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon \u03b1-2a (40 kd)\/ribavirin therapy","volume":"43","author":"Jensen","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib17","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/j.gastro.2006.02.015","article-title":"Extended treatment duration for hepatitis C virus type 1\u00a0: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin","volume":"130","author":"Berg","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lpm.2008.12.037_bib18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2006.05.016","article-title":"Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment","volume":"131","author":"Sanchez-Tapias","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lpm.2008.12.037_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jhep.2005.10.003","article-title":"Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia","volume":"44","author":"Zeuzem","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.lpm.2008.12.037_bib20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2005.05.016","article-title":"International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C","volume":"43","author":"Zeuzem","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.lpm.2008.12.037_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa066403","article-title":"Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3","volume":"357","author":"Shiffman","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2008.12.037_bib22","first-page":"291A","article-title":"Pegylated interferon alfa-2A (40KD) plus ribavirin (RBV) in prior non-responders to pegylated interferon \u03b1-2B (12KD)\/RBV\u00a0: Final efficact and safety outcomes of the repeat study","volume":"46","author":"Jensen","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib23","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/hep.22448","article-title":"Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics\u00a0: Randomized study of higher doses of peginterferon \u03b1-2a and ribavirin","volume":"48","author":"Fried","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/hep.21712","article-title":"Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin \u03b1","volume":"46","author":"Shiffman","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib25","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0168-8278(06)80114-5","article-title":"A Phase 2 dose-escalation study of albuferon combined with ribavirin in non-responders to prior interferon-based therapy for chronic hepatitis C infection","volume":"44","author":"Rustgi","year":"2006","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib26","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1053\/j.gastro.2004.08.002","article-title":"Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients","volume":"127","author":"Hinrichsen","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lpm.2008.12.037_bib27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature02099","article-title":"An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus","volume":"426","author":"Lamarre","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.lpm.2008.12.037_bib28","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/hep.20612","article-title":"Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C","volume":"41","author":"Reiser","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib29","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/hep.21774","article-title":"Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C","volume":"46","author":"Forestier","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib30","doi-asserted-by":"crossref","first-page":"S4-S","DOI":"10.1016\/S0168-8278(08)60006-9","article-title":"Results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C","volume":"48","author":"McHutchison","year":"2008","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib31","doi-asserted-by":"crossref","first-page":"S26-S","DOI":"10.1016\/S0168-8278(08)60060-4","article-title":"Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon-alfa-2a with or without ribavirin\u00a0: Further interim analysis results of the PROVE2 study","volume":"48","author":"Dusheiko","year":"2008","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib32","doi-asserted-by":"crossref","first-page":"S46-S","DOI":"10.1016\/S0168-8278(08)60106-3","article-title":"Boceprevir (B) combination therapy in null responders (NR)\u00a0: Response dependent on interferon responsiveness","volume":"48","author":"Schiff","year":"2008","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib33","doi-asserted-by":"crossref","first-page":"S372-S","DOI":"10.1016\/S0168-8278(08)60997-6","article-title":"Interim results from HCV sprint-1\u00a0: RVR\/EVR from phase 2 study of boceprevir plus pegintrontm (peginterferon alfa-2b)\/ribavirin in treatmentnaive subjects with genotype-1 CHC","volume":"48","author":"Kwo","year":"2008","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib34","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lpm.2008.12.037_bib35","first-page":"A779-A","article-title":"Viral load and ALT reductions associated with R1626 monotherapy, a novel nucleoside analog, in chronic hepatitis C genotype 1 patients","volume":"132","author":"Roberts","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lpm.2008.12.037_bib36","article-title":"Phase 1 evaluation of antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with different pegylated interferons in the treatment-naive patients with chronic HCV","volume":"46","author":"Villano","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib37","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/hep.21773","article-title":"Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus","volume":"46","author":"McHutchison","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib38","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/hep.20839","article-title":"Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection","volume":"42","author":"Horsmans","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.lpm.2008.12.037_bib39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jhep.2007.02.018","article-title":"Virological response and safety outcomes in therapy-ndive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a\u00a0: A randomized, phase 2 study","volume":"47","author":"Gish","year":"2007","journal-title":"Journal of Hepatology"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498209002267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498209002267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T19:28:34Z","timestamp":1544729314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498209002267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0755498209002267"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2008.12.037","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}